Image (0ed6c856 4d95 4aeb B925 15346555a2ab 565 2)
Topiramate Tablet, Film Coated
Product Images NDC 83008-011
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 83008-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image Description (25mg)
Label for Topiramate Tablets USP 25 mg, 60 tablets per bottle. Distributed by Quality Care Products, LLC, Holland, OH. Manufactured by Unichem Laboratories Ltd., India, for Unichem Pharmaceuticals (USA), Inc. Directions to store at 68 to 77 degrees Fahrenheit and notes to dispense with medication guide are shown.*
Image Description (50mg)
Topiramate Tablets USP 50 mg label indicating a 60-tablet count. The label shows Quality Care Products, LLC as the packager and distributor with a contact number. Manufactured by Unichem Laboratories Ltd. in India for Unichem Pharmaceuticals (USA), Inc. Storage instructions specify temperature control. The label includes NDC 83008-011-60 and a note to keep medication out of children's reach.*
Image (A3c0c9f1 34be 43b2 A33a Bda648fa93d2 01)
Chemical structure of topiramate, showing its molecular arrangement including sulfur, oxygen, nitrogen, and carbon atoms as part of its chemical composition.*
Image (A3c0c9f1 34be 43b2 A33a Bda648fa93d2 02)
A cumulative rate line graph depicting time to first seizure over 500 days for two topiramate dosage groups, 50 mg/day and 400 mg/day, with sample sizes noted (N=234 and N=236). The y-axis shows cumulative rates for time to first seizure, and the graph indicates a statistically significant difference with a p-value of 0.0002.*
Image (A3c0c9f1 34be 43b2 A33a Bda648fa93d2 03)
Bar chart showing change from baseline to double-blind phase in average monthly migraine period rate for placebo and topiramate at 50 mg/day, 100 mg/day, and 200 mg/day doses. Data are presented from two studies, labeled Study 1 and Study 2, with statistical significance indicated for topiramate dose groups compared to placebo.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
